Cetaphil AI Visibility Market Strategy Report - Sunscreen Brands

Answer Capsule

Cetaphil holds 31.7% valid recommendation coverage in the October 2026 LLM Authority Index sunscreen benchmark, placing it sixth of nine tracked brands. The brand is visible in 33.9% of qualified observations but converts that presence into a valid recommendation in fewer than one in three cases, and its top-three placement rate of 14.8% sits well below the category's leading cluster. The clearest win is a recovery of 11.6 percentage points from September to October, the largest single-month move recorded for the brand in this series. The clearest weakness is first-position share of 2.1%, which leaves Cetaphil almost entirely absent from the answers where a single brand is named first.

Who This Report Is For

This report is written for Cetaphil's brand, ecommerce, and category marketing leadership, and for the retail and dermatology-channel partners who need to understand how AI systems are framing the brand at the discovery and consideration stage.

Report Card

Executive Summary

Cetaphil closed October 2026 with 31.7% valid recommendation coverage across 622 qualified observations, a figure that is essentially flat against the July 2026 baseline of 32.0%. That flatness is misleading. The intervening months were not flat at all: the brand fell to 27.8% in August and 20.1% in September before recovering 11.6 percentage points in October, the largest single-month move recorded for Cetaphil in this series. The current position therefore reflects a sharp rebound from a September trough rather than a stable mid-table standing.

The gap between presence and recommendation is the defining feature of Cetaphil's AI footprint. The brand appears in 33.9% of qualified observations but receives a valid recommendation in only 31.7%, a conversion gap of 2.2 percentage points. That gap is small in absolute terms, but it matters because Cetaphil's presence rate is itself modest. The brand is mentioned in roughly one in three answers and recommended in roughly one in three, which means it is neither broadly surfaced nor reliably shortlisted.

Placement is where Cetaphil is weakest. The brand's top-three rate of 14.8% is less than a third of La Roche-Posay's 72.0% and roughly half of Neutrogena's 31.8%. First-position share is 2.1%, or 13 observations out of 622, compared with EltaMD's category-leading 31.4%. Cetaphil is occasionally part of the shortlist and almost never the answer.

The strongest platform signal for Cetaphil is Perplexity, where the brand reaches 39.2% valid recommendation coverage and a 9.5% rank-one rate, both above its category-wide figures. The weakest is Copilot, where coverage falls to 16.5% and rank-one share to 1.3%. Google AI Overviews carries the largest single-platform recommendation volume for the brand at 30.7% coverage, but that still trails the category leaders by a wide margin on the same surface.

Sentiment is not the problem. Cetaphil recorded 199 positive mentions, 12 neutral mentions, and zero negative mentions in October 2026, producing a net sentiment score of 0.9431. The brand is framed favorably wherever it appears. The issue is that it appears in too few of the answers that matter and is placed first in almost none of them.

The clearest opportunity sits in the same cluster where the entire category competes: Best Dermatologist Recommended Skin Care Brands. Cetaphil's September-to-October recovery shows the brand can move meaningfully within a single month when the prompt mix shifts in its favor. The question the benchmark cannot answer is which prompts drove that recovery and which prompts still leave the brand out entirely.

What Cetaphil Is Winning

Questions This Section Answers

• What drove Cetaphil's 11.6-point recommendation coverage gain from September to October?
• Which platform gives Cetaphil its strongest recommendation and rank-one performance?
• How does Cetaphil's sentiment compare to the category leaders despite lower coverage?

Cetaphil's strongest evidence-backed win is its October recovery. Valid recommendation coverage rose 11.6 percentage points from September to October 2026, the largest single-month move recorded for the brand across the tracked series. That move was placement-led rather than presence-led: raw mention presence slipped 2.7 percentage points to 33.9%, while top-three rate rose 4.9 percentage points to 14.8%. The brand converted a similar volume of mentions into more shortlist placements.

The second win is sentiment quality. Cetaphil recorded zero negative mentions across 622 qualified observations, with 199 positive and 12 neutral. A net sentiment score of 0.9431 places the brand in the same favorable framing band as La Roche-Posay (0.9765) and CeraVe (0.9636), even though its coverage is far lower. Where Cetaphil is mentioned, AI systems frame it positively.

The third win is platform-specific strength on Perplexity. Cetaphil reaches 39.2% valid recommendation coverage on Perplexity, its highest across the six tracked surfaces, and a 9.5% rank-one rate that is more than four times its category-wide first-position share. Perplexity is a narrow but real recommendation pocket for the brand.

These wins are real but modest. Cetaphil does not hold a dominant position on any platform, does not lead any cluster, and does not appear in the top three of any category-wide placement metric.

Where Cetaphil Has the Clearest AI Visibility Gaps

Questions This Section Answers

• Where does Cetaphil lose the most ground to competitors like EltaMD, La Roche-Posay, and CeraVe?
• How far behind is Cetaphil on top-three and first-position placement?
• Why does Cetaphil's value positioning have no measurable AI recommendation signal?

The clearest gap is first-position displacement. Cetaphil's rank-one rate of 2.1% means the brand is named first in 13 of 622 qualified observations. EltaMD is named first in 195. La Roche-Posay is named first in 117. CeraVe is named first in 125. When an AI system answers a sunscreen discovery question with a single lead recommendation, Cetaphil is almost never that answer.

The second gap is top-three displacement. Cetaphil's 14.8% top-three rate places it sixth of nine tracked brands, behind La Roche-Posay (72.0%), EltaMD (53.2%), CeraVe (48.9%), Neutrogena (31.8%), and Supergoop (26.4%). The brand is shortlisted in roughly one in seven qualified observations. The four brands above it on this metric are shortlisted in roughly one in two or better.

The third gap is presence breadth. Cetaphil's raw mention presence rate of 33.9% is less than half of La Roche-Posay's 95.8%, CeraVe's 79.6%, Neutrogena's 75.7%, and EltaMD's 74.4%. The brand is absent from roughly two thirds of the qualified answer set. Supergoop, despite a 13.3-point coverage decline since July, still appears in 54.0% of observations. Cetaphil appears in 33.9%.

The fourth gap is platform inconsistency. Cetaphil's coverage ranges from 16.5% on Copilot to 39.2% on Perplexity, a spread of 22.7 percentage points. On Copilot, the brand records a 1.3% rank-one rate and a 6.3% top-three rate. On Google AI Mode, coverage is 31.6% with a 2.6% rank-one rate. The brand's recommendation behavior is uneven across surfaces, which suggests the underlying source and prompt patterns differ by platform.

The fifth gap is the absence of pricing and comparison signal. All 622 qualified observations in October 2026 fell into the Brand Recommendation cluster. No qualified observations were recorded for pricing and value or multi-brand comparison questions. Cetaphil's value positioning, which is a core part of its brand identity in the skincare category, has no measurable AI recommendation signal in this benchmark.

Biggest Opportunity

Questions This Section Answers

• How could Cetaphil reach a top-three shortlist rate closer to Neutrogena's?
• Which platforms offer the largest top-three placement upside for Cetaphil?

Cetaphil's clearest path from reference to recommendation is to convert its existing positive framing into top-three placement within the Best Dermatologist Recommended Skin Care Brands cluster. The brand already appears in roughly one in three qualified observations and is framed positively in 94.3% of those mentions. What it does not do is land in the shortlist at a rate that matches its presence.

The October recovery shows this is achievable. A 4.9-point top-three gain came from a 2.7-point presence decline, which means the brand moved into shortlist positions in answers where it was already being mentioned. The opportunity is to extend that pattern across the full prompt set, particularly on Copilot and Google AI Mode, where Cetaphil's top-three rates of 6.3% and 17.8% sit well below its Perplexity rate of 29.7%.

Closing even half of the gap between Cetaphil's 14.8% top-three rate and Neutrogena's 31.8% would move the brand from sixth to fifth in the category on placement, and would do so without requiring a change in how often the brand is mentioned.

Competitive Landscape

Questions This Section Answers

• Where does Cetaphil sit among the nine tracked sunscreen brands on top-three and rank-one rates?
• When Cetaphil does enter the shortlist, where does it typically land?

La Roche-Posay holds dominant recommendation power in the sunscreen category, with CeraVe, EltaMD, and Neutrogena forming a strong second tier. Cetaphil sits in the middle of the field, ahead of Sun Bum, Vichy, and Kopari Beauty but well behind the four brands that convert presence into shortlist placement at scale.

Average recommended rank covers rank-eligible recommendations only.

Cetaphil's position in the table shows a brand with mid-table shortlist inclusion and near-absent first-position strength. Its 14.79% top-three rate is roughly half of Neutrogena's and less than a third of CeraVe's, while its 2.09% rank-one rate is the second-lowest among brands with any rank-one credit at all. The average recommended rank of 3.40 is competitive with Neutrogena's 3.46 and Supergoop's 3.13, which indicates that when Cetaphil does enter the shortlist, it typically lands in the middle of the list rather than at the top.

Prompt Evidence

Google AI Overviews / Best Dermatologist Recommended Skin Care Brands Prompt: "What is the best mineral sunscreen for rosacea?" Result: Cetaphil was mentioned and recommended, contributing to its 30.7% coverage on this surface, but did not reach a top-three position in the observed answer.

Perplexity / Best Dermatologist Recommended Skin Care Brands Prompt: "Which sunscreen is best for combination skin?" Result: Cetaphil reached a valid recommendation and contributed to its strongest platform result, with a 39.2% coverage rate and a 9.5% rank-one rate on Perplexity.

Copilot / Best Dermatologist Recommended Skin Care Brands Prompt: "What are the top 10 best skincare brands?" Result: Cetaphil was mentioned but placed outside the top three, consistent with its 6.3% top-three rate and 1.3% rank-one rate on Copilot.

ChatGPT / Best Dermatologist Recommended Skin Care Brands Prompt: "Which is the best moisturizer to use?" Result: Cetaphil received a valid recommendation but no first-position credit, reflecting its 3.5% top-three rate and 0.0% rank-one rate on ChatGPT.

What CiteWorks Studio Would Do Next

Phase 1: AI Visibility Market Discovery Audit Map the specific prompts where Cetaphil is mentioned but not shortlisted, and identify which competitors absorb the top-three positions in those same answers.

Phase 2: Recommendation Readiness Plan Prioritize the Copilot and Google AI Mode surfaces where Cetaphil's top-three rate falls well below its Perplexity performance, and define the placement targets for each.

Phase 3: Owned Answer Layer Buildout Strengthen the owned pages and product content that AI systems retrieve when forming dermatologist-recommended sunscreen answers, with emphasis on the attributes that drive shortlist inclusion.

Phase 4: Citation / Authority Layer Development Build the editorial, dermatology, and retail source footprint that supports Cetaphil's presence in the citation layer, where no tracked brand's own domain currently appears in the top 10 cited domains.

Phase 5: Monthly AI Visibility and Recommendation Tracking Track Cetaphil's coverage, top-three rate, and rank-one rate month over month to confirm whether the October recovery holds or reverses.

Why This Matters

Questions This Section Answers

• What is the difference between being mentioned in AI sunscreen answers and being recommended as a leading option?
• What kind of fix does Cetaphil's mention-to-recommendation gap require?

AI presence alone is not enough. Cetaphil is mentioned in one in three qualified sunscreen answers and framed positively in nearly all of them, yet it is shortlisted in only one in seven and named first in one in fifty. A buyer asking an AI system which sunscreen to choose will see Cetaphil referenced, but will rarely see it recommended as a leading option. That is a different problem from being absent, and it requires a different fix.

The next move is targeted correction of the prompt, page, and citation layers that determine where Cetaphil lands once it is mentioned. The October recovery shows the brand can move within a single month when those layers align. The benchmark identifies where the movement happened; a company-level analysis identifies which prompts, surfaces, and sources produced it.

Core Metrics

Sentiment Score

Sentiment Score = (positive mentions × 1 + neutral mentions × 0 + negative mentions × -1) / total mentions

For Cetaphil in October 2026: (199 × 1 + 12 × 0 + 0 × -1) / 211 = 0.9431.

This matters because unclassified mention counts are misleading. A brand that appears in 211 answers but is framed neutrally or negatively is not in the same position as a brand that appears in 211 answers and is framed positively. Cetaphil's 0.9431 score places it in the favorable framing band alongside the category leaders, which means the brand's problem is not how it is described when it appears. The problem is how often it appears and where it is placed.

Share of voice is a diagnostic metric, not a business KPI. A positive recommendation, a neutral reference, a cautionary mention, and a competitor-displaced mention are not equal. Counting all mentions as wins is bad measurement. Classified sentiment is required before interpreting AI visibility, because a brand with high presence and low sentiment is in a weaker position than a brand with lower presence and consistently positive framing. Cetaphil sits in the second category: modest presence, strong framing, weak placement.

Sentiment by Platform

Methodology

1. This report is a benchmark-based analysis of Cetaphil's AI recommendation visibility in the Sunscreen Brands category for October 2026. It is not a client implementation case study and does not imply that any remediation work has been performed.
2. The reporting window is October 2026, with comparison points from July 2026, August 2026, and September 2026 where the source benchmark provides them.
3. Six AI and search surface families were tracked: ChatGPT, Copilot, Gemini, Perplexity, Google AI Overviews, and Google AI Mode. All six carried at least one qualified observation in October 2026.
4. The October 2026 run began with 800 prompt-surface observations and 653 unique questions. After qualification, 622 observations formed the public denominator used for all brand-level percentages.
5. The competitor universe consists of nine tracked brands: CeraVe, Cetaphil, EltaMD, Kopari Beauty, La Roche-Posay, Neutrogena, Sun Bum, Supergoop, and Vichy.
6. One public high-intent cluster carried sufficient data in October 2026: Best Dermatologist Recommended Skin Care Brands, classified as a consideration-stage cluster. Two additional clusters, covering brand comparisons and pricing and value, recorded no qualified observations.
7. Stage 0 extraction supplied the prompt-level observations, platform attribution, recommendation placement, sentiment classification, and citation data used in this report.
8. A mention is counted when Cetaphil appears anywhere in a qualified AI response, regardless of whether it is recommended. Raw mention presence rate is the share of qualified observations where the brand is mentioned at all.
9. A valid recommendation is counted when the dataset explicitly marks Cetaphil as a recommended option. Neutral references, comparison anchors, and listed-only mentions are not counted as valid recommendations.
10. Top-three rate is the share of qualified observations where Cetaphil appears in the top three recommended positions. Rank-one rate is the share where Cetaphil is the first recommended option. Average recommended rank covers rank-eligible recommendations only.
11. Unique prompt count for the public version is not separately reported beyond the 653 unique questions figure. The benchmark does not publish a per-brand prompt-level breakdown.
12. Limitations: the benchmark does not measure market share, sales attribution, organic search ranking, social mention volume, or causality from any metric movement. Pricing and multi-brand comparison questions have no qualified signal in this dataset, so Cetaphil's value positioning cannot be assessed from this benchmark alone.

See How AI Is Recommending Your Brand

The public benchmark shows where Cetaphil stands in AI-generated sunscreen recommendations. A company-level AI visibility audit maps the specific prompts, competitors, surfaces, and sources behind that position, and turns the category standings into a prioritized plan for moving from mention to shortlist.